Feb 24, 2022 8:00 AM EST. Relations. View Webcast. watertown, mass., april 10, 2021 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively. 1700 Owens Street, Suite 205 San Francisco, CA 94158. Biogen Planned Acquisition of Nightstar Therapeutics. C4 Therapeutics is funded by 23 investors. 9.7 MB. Sema4 Investor Deck- May 2022 8.2 MB Sema4's Mission Sema4 - Mission Video Watch on Events Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia ("FM"). Horizon Contacts: Tina Ventura Senior Vice President, Investor Relations Investor-relations . Overview. IR@Virios.com. watertown, mass., april 08, 2022 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation. Firm. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. 24256790 Earnings Release. Quarterly Filing (10-Q/10-K) Transcript. Below is a list of individuals that we're aware of that currently follow Inhibrx. Mar 25, 2022. SE. Investor Relations. Listen to webcast. Vice President, Investor Relations 978.600.7717 dgordon@insulet.com ir@insulet.com. View Webcast. . Please note that any opinions, estimates, or forecasts regarding performance made by these analysts don't represent Inhibrx or its management team. If you experience any issues with this process, please contact us for further assistance. Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis. C4 Therapeutics has raised a total of $423.8M in funding over 4 rounds. Their latest funding was raised on Jun 14, 2021 from a Post-IPO Equity round. More events are coming soon. Feb 16, 2022 8:00 AM EST. Our Opportunity: C4 Therapeutics, Inc. (C4T) is searching for an Associate Director of Investor Relations (IR) to become part of an expanding Communications and Investor Relations team. Search and apply for the latest Investor relations jobs in Newton Center, MA. Novo Nordisk A/S Novo Allé 1 2880 Bagsværd Denmark +45-4444-8888 CVR-no. For more information, please visit www.c4therapeutics.com . At Travere Therapeutics, our global team works with the rare disease community to identify, develop and deliver life-changing therapies. 31, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022 . C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors; Trending News. Last Price Change Volume 52 Week High 52 Week Low The Investor Relations website contains information about PTC Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. The Investor Relations website contains information about Vera Therapeutics's business for stockholders, potential investors, and financial analysts. After submitting your request . Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and . May 4, 2022 at 4:30 PM EDT. ET on January 28, 2021 until 7:30 p.m. 1Q22 Supplemental Slides. For more information, please visit www.c4therapeutics.com . The Investor Relations website contains information about Dyne Therapeutics's business for stockholders, potential investors, and financial analysts. . (opens in new window) February 17, 2022. Read more. Vertex Pharmaceuticals Fourth Quarter 2019 Earnings Conference Call. Analyst Coverage. Biogen Analyst Q&A Call. Schrödinger First Quarter 2022 Financial Results Conference Call. Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. Q1'2022 Earnings Slides 1.9 MB. The Investor Relations website contains information about Prelude Therapeutics's business for stockholders, potential . . Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights 05.11.22. Direct: 415-660-5320 Fax: 415-525-4200. info@nurix-inc.com We are dedicated to improving human health by unlocking the power of the genome. Investor Presentation. In the last year C4 Therapeutics saw its revenue grow by 13%. Investor Contact Hannah Deresiewicz Stern Investor Relations, Inc. hannah . Webcast. Feb 18, 2022 at 9:20 AM EST. At Mirati Therapeutics Inc., we promise to treat your data with respect and will not share your information with any third party. 1700 Owens Street, Suite 205 San Francisco, CA 94158. Lauren Paige Executive Assistant 978.600.7835 lpaige@insulet.com. Proxy Statement. We are advancing a rich pipeline of investigational microbiome therapeutics designed to address a wide range of unmet medical needs, with a candidate in late-stage clinical development for recurrent C. difficile infection and candidates for inflammatory bowel disease and autism spectrum disorder in pre-clinical development.. Media: LifeSci Communications, LLC Josephine Belluardo, Ph.D. 646-751-4361 jo@lifescicomms.com www.lifescicommunications.com. Kymera is . To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Upcoming Events. Electronic trading poses unique risk to investors. Documents. A global leader in DNA sequencing and array-based technologies, Illumina is fueling advancements in life sciences, oncology, reproductive health, genetic disease, agriculture, microbiology, and other emerging segments. Sea Limited Reports First Quarter 2022 Results. The ideal candidate will help to proactively implement and manage C4T's investor relations program. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the 'unsubscribe' section below. The Investor Relations website contains information about Travere Therapeutics, Inc. 's business for stockholders, potential investors, and financial analysts. . Fireside chat scheduled for Thursday, April 28, 2022 at 12:30 PM ET NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in a fireside . Past performance of a security, market, or financial product does not guarantee future results. Contact. Events & Presentations. . Firm. Sage Therapeutics Q4 2021 Financial Results Conference Call. 2022. G1 Therapeutics, Inc. is a commercial stage oncology company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer. Job email alerts. The Investor Relations website contains information about Monte Rosa Therapeutics's business for stockholders, potential investors, and financial analysts. JMIA. Learn more Jun 05, 2019. New York, NY 10004-1561. cstmail@continentalstock.com. Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. Candel's products are designed to improve survival while maintaining quality of life - from early- to late-stage disease. Protagonist Therapeutics Reports Granting of Inducement Awards. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect . Learn more about our pipeline here. watertown, mass., may 16, 2022 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in … Compounds derived from Shattuck's ARC platform simultaneously inhibit checkpoint molecules and activate costimulatory . Transfer Agent. - Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C - - Phase 1/2 Clinical Trial Initiated for CFT8634, a BRD9 Degrader, for Patients with Synovial Sarcoma and SMARCB1-null Solid Tumors - - Potential of TORPEDO® Platform Demonstrated at AACR with Pre-clinical . Read more. Conference and Other Investor Presentations. Our Opportunity C4 Therapeutics, Inc. (C4T) is searching for a Senior Manager of Investor Relations (IR) to become part of an expanding. Rubius Therapeutics developed our proprietary RED PLATFORM® to generate red blood cells and genetically engineer them into a new class of cellular medicines, called Red Cell Therapeutics . showing 1-3 of 3. Our Opportunity: C4 Therapeutics, Inc. (C4T) is searching for an Associate Director of Investor Relations (IR) to become part of an expanding Communications and Investor Relations team. Sema4 is transforming healthcare by applying artificial intelligence and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. LENSAR Inc. Fourth Quarter 2021 Financial Results Conference Call. The modest growth is probably largely reflected in the share. 73 open jobs for Senior director investor relations in Manchester. . 04/19/2022. Jan 10, 2022. Investors G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product COSELA™ (trilaciclib). Analyst Coverage. Merrill Robichaud Investor Relations Coordinator 978.932.0444 mrobichaud@insulet.com. . Read more. . J.P. Morgan 40th Annual Healthcare Conference. Novavax will host a conference call today at 4:30pm ET. ET on February 4, 2021. The Investor Relations website contains information about Jounce Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. April 7, 2022. . 04/25/2022. Delivering Value to Investors. 4634 M. 45°56′12.6″N. Oct 22, 2019. March 03, 2022. . View Presentation. Listen to webcast. Box 1342 Brentwood, NY 11717 T: 877-830-4936 . That's not a very high growth rate considering it doesn't make profits. Mar 04, 2019. Financial Document Library. All investments involve risk, including possible loss of principal. Vera's mission is to advance treatments that target the . 01 Mar. Investors. Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. October 18, 2021. at 10:00 AM PDT. SAN DIEGO -- (BUSINESS WIRE)--Mar. Competitive salary. Supporting Materials. Investor Relations Corporate Profile Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. November 2, 2021. at 1:30 PM PDT. Skip to main navigation Toggle navigation Our goals are big. . Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer. Investors & Media Home. Skip to main navigation Monte Rosa. Please note that any opinions, estimates, or forecasts regarding performance made by these analysts don't represent Inhibrx or its management team.